Agenus is an immuno-oncology company driven by innovation and speed. Our goal is to treat cancers with novel combinations utilizing our unique portfolio of checkpoint antibodies, tumor microenvironment modifiers, vaccines and adjuvants. In addition to a broad portfolio, we have an accomplished team of scientists, novel technology platforms and fully-integrated end-to-end capabilities from discovery to GMP manufacturing. With our remarkable combination of science and people, we believe that we are uniquely positioned to bring curative treatments to cancer patients. For more information, please visit www.agenusbio.com; information that may be important to investors will be routinely posted on our website. Follow @Agenus_Bio on Twitter to stay up to date! https://twitter.com/Agenus_Bio